Identification of consistent novel submegabase deletions in low-grade oligodendrogliomas using array-based comparative genomic hybridization

被引:26
作者
Rossi, MR
Gaile, D
LaDuca, J
Matsui, SI
Conroy, J
McQuaid, D
Chervinsky, D
Eddy, R
Chen, HS
Barnett, GH
Nowak, NJ
Cowell, JK
机构
[1] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA
[2] Roswell Pk Canc Inst, Dept Biostat, Buffalo, NY 14263 USA
[3] SUNY Buffalo, Dept Biostat, Buffalo, NY 14260 USA
[4] SUNY Buffalo, Ctr Excellence Bioinformat, Buffalo, NY 14260 USA
[5] Cleveland Clin Fdn, Dept Neurosurg, Cleveland, OH 44195 USA
关键词
D O I
10.1002/gcc.20218
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have analyzed 18 low-grade gliomas using array comparative genomic hybridization (aCGH) with an average resolution of < 500 kb. Because the majority of these tumors showed loss of chromosome arms 1p and 19q, we used custom statistical approaches to define submegabase hemizygous losses throughout the genome that correlated with 19q loss. As a result of this analysis, we have identified a similar to 550-kb region in 11q13 and a similar to 300-kb region in 13q12 that showed hemizygous deletion in virtually all the tumors analyzed regardless of their 1p/19q status. FISH analyses of interphase nuclei from the same tumors used for aCGH analysis confirmed the hemizygous loss. The identification of such specific changes provides a potentially very useful diagnostic marker for this subgroup of low-grade tumors. These regions of the genome define small numbers of candidate genes that are within the deletions. The aCGH analysis also defined the spectrum of gain and loss of genomic regions in low-grade oligodendrogliomas. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:85 / 96
页数:12
相关论文
共 33 条
[1]   Genomic microarrays in human genetic disease and cancer [J].
Albertson, DG ;
Pinkel, D .
HUMAN MOLECULAR GENETICS, 2003, 12 :R145-R152
[2]  
[Anonymous], 2000, World Health Organisation Classification of Tumours: Pathology and genetics of tumours of the nervous system
[3]  
[Anonymous], 1993, Resampling-based multiple testing: Examples and methods for P-value adjustment
[4]  
ASHBY LS, 2004, CURR NEUROL NEUROSCI, V3, P211
[5]  
BELLOTTO M, 1995, PHYS CHEM MINER, V22, P207, DOI 10.1007/BF00202253
[6]   Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: Efficacy and associations with chromosomal abnormalities [J].
Buckner, JC ;
Gesme, D ;
O'Fallon, JR ;
Hammock, JE ;
Stafford, S ;
Brown, PD ;
Hawkins, R ;
Scheithauer, BW ;
Erickson, BJ ;
Levitt, R ;
Shaw, EG ;
Jenkins, R .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :251-255
[7]  
Burton EC, 2002, CANCER RES, V62, P6205
[8]  
Burton EC, 2002, CLIN CANCER RES, V8, P180
[9]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[10]   Molecular definition of chromosome translocations involving 10q24 and 19q13 in human malignant glioma cells [J].
Chernova, O ;
Cowell, JK .
CANCER GENETICS AND CYTOGENETICS, 1998, 105 (01) :60-68